ASS1 Antibody

1. In ASS1-knockout cells, DEPTOR, an inhibitor of mTORC1 signal, was downregulated and mTORC1 signaling was more activated in response to arginine. PMID: 28358054
2. Results indicate that the reduced ASS1 expression in Dox-resistant sarcomas may contribute to drug resistance in association with the expression of P-glycoprotein. PMID: 27683125
3. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1alpha, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. PMID: 27765932
4. Low expression of ASS1 is associated with glioblastoma. PMID: 27431689
5. defined a new hepatocellular adenoma subgroup at a high risk of bleeding PMID: 28646562
6. ASS1 acetylation by CLOCK exhibits circadian oscillation in human cells and mouse liver, possibly caused by rhythmic interaction between CLOCK and ASS1, leading to the circadian regulation of ASS1 and ureagenesis. PMID: 28985504
7. update reports 137 mutations in the ASS1 gene (64 of which are novel), consisting of 89 missense mutations, 19 nonsense mutations, 17 mutations that affect splicing, and 12 deletions; the change p.Gly390Arg is by far the most common mutation and is widely spread throughout the world PMID: 28111830
8. Of 21 ASS potential kinetic mutations, 13 were totally inactive while 8 exhibited decreased affinity for aspartate and citrulline. PMID: 27287393
9. Low ASS1 expression was associated with higher recurrence , shorter disease-free survival and shorter overall survival in patients with pancreatic ductal adenocarcinoma. PMID: 28187218
10. The s showed that ASS1 mutations linked to type I citrullinemia disrupt the ASS1-PRMT7 interaction, which might explain the molecular pathogenesis of the disease. PMID: 28587924
11. Identification of three novel CTLN1 mutations in fourteen patients with citrullinemia type 1 has been reported. PMID: 28132756
12. In this trial, arginine deprivation with ADI-PEG20 improved PFS in patients with ASS1-deficient mesothelioma. Targeting arginine is safe and warrants further clinical investigation in arginine-dependent cancers. PMID: 27584578
13. combining hypoxia and ADI-PEG20 synergistically inhibited ASS1. PMID: 26972697
14. ASS1 genomic variants (rs10901080 and rs10793902) can serve as pharmacogenomic biomarkers to predict hydroxyurea treatment efficacy in sickle cell disease/beta-thalassemia compound heterozygous patients. PMID: 26895070
15. results show that ASS1 is elevated at the mRNA and protein levels in mesothelioma 3D spheroids and in human pleural mesotheliomas. We also have uncovered a survival role for ASS1 PMID: 26982031
16. results demonstrate that ASS1 downregulation is a novel mechanism supporting cancerous proliferation, and they provide a metabolic link between the urea cycle enzymes and pyrimidine synthesis PMID: 26560030
17. More than 50 % of the high-grade pulmonary neuroendocrine carcinomas tested lack immunohistochemically detectable ASS, suggesting that they are auxotrophic for arginine and potential candidates for arginine deprivation therapy. PMID: 25548129
18. Three novel splicing and missense mutations have been identified in the ASS1 gene in classical citrullinemia patients. PMID: 25179242
19. ASS expression in gastric cancer was associated with a poor prognosis. PMID: 25333458
20. we reviewed the English literature on mutations in the ASS and SLC25A13 genes, and their genotype-phenotype correlations to provide valuable insights into the molecular genetic background of citrullinemia--{REVIEW} PMID: 24508627
21. Data indicate that argininosuccinate synthetase 1 (ASS1) abundance is a prognostic factor for overall breast cancer survival. PMID: 24692592
22. Argininosuccinate synthetase gene is silenced by CpG methylation in children with phenylketonuria.The promoter of argininosuccinate synthetase was methylated which silence the transcription of argininosuccinate synthetase. PMID: 24192130
23. Aberrant loss of ASS1 strongly links to DNA methylation in neck nodal metastases of NPC and significantly correlates with advanced T classification, and independently predicts worse DSS and DMFS in independent NPC tissue specimens. PMID: 23897555
24. Together with the observation that AS1 protein and mRNA levels decrease during wild-type infection, this work suggests that reduced AS1 activity is partially responsible for the metabolic program induced by infection. PMID: 24297925
25. Our findings highlight ASS1 as a novel tumor suppressor in myxofibrosarcomas, with loss of expression linked to promoter methylation, clinical aggressiveness, and sensitivity to ADI-PEG20. PMID: 23549872
26. ASS expression is decreased significantly in hepatocellular carcinoma tissues. PMID: 23339388
27. Mutations are identified only in exons of ASS1 gene from the Korean patients with citrullinemia type I. PMID: 23099195
28. The present study demonstrated a key regulatory role of KLF4 in the endothelial ASS1 expression and NO production in response to laminar shear stress. PMID: 22430140
29. The ASS release represents a potential counteracting liver reaction to LPS. PMID: 21481813
30. the expression of ASS1 harmonized with that of NOS3 may be important for the optimized endothelial NO production and the prevention of the inflammatory monocyte adhesion to endothelial cells. PMID: 21106532
31. Analysis of five SNPs of the ASS1 gene revealed that the G allele of rs7860909 is associated with increased CL/P risk. PMID: 20739017
32. In patients with osteosarcoma, reduced expression of ASS is not only a novel predictive biomarker for the development of metastasis, but also a potential target for pharmacologic intervention. PMID: 20159990
33. Studies indicate that the proximal region of the AS promoter contains an E-box that is recognized by c-Myc and HIF-1alpha and a GC-box by Sp4. PMID: 19934275
34. Mutational analysis revealed three alleles with a common mutation and five new mutations. PMID: 11708871
35. structure and use in diagnosing citrullinemia PMID: 11941481
36. Sixteen novel mutations have been identified in the argininosuccinate synthetase gene in citrullinemia patients. PMID: 12815590
37. argininosuccinate synthetase gene expression is stimulated by glutamine through cytosolic O-glycosylation of Sp1 in tumor cells PMID: 14570901
38. Argininosuccinate synthetase has a role in preventing autotoxicity from nitric oxide overproduction PMID: 15192091
39. Extensive mutation study by direct genomic sequencing of ASS demonstrated a homozygous G117S mutation in one patient and homozygous R363W mutations in the other two families PMID: 16124451
40. IL-1beta induces nitric oxide which has antagonistic effects on argininosuccinate synthetase gene and on the activity of argininosuccinate synthetase PMID: 16380201
41. ASS, the c-myc-regulated gene is involved in genotype-C-HBV-related HCC, suggesting that c-myc is related to the hepatocarcinogenic activity of genotype-C HBV. PMID: 16703398
42. Low argininosuccinate synthetase is associated with renal cell carcinoma PMID: 17096330
43. high levels of AS expression, which may be required for several arginine-dependent processes in cancer, including the production of nitric oxide, proline, pyrimidines and polyamines, is regulated by TNF-alpha PMID: 17354225
44. HSCARG regulation of argininosuccinate synthetase activity is crucial for maintaining the intracellular balance between redox state and nitric oxide levels PMID: 18263583
45. These results show that liver-specific enhancement of ASS gene expression is mediated in part by the cAMP signaling pathway through a distal CRE site. PMID: 18840401
46. argininosuccinate synthetase behaves as a typical suckling enzyme because its expression all but disappears in the putative weaning period of human infants. PMID: 19000307
47. a survey of the correlation between mutations in the ASS1 gene and the respective clinical courses of citrullinemia type I as described so far (Review) PMID: 19006241
48. The studied families showed the same mutation: ASS~p.G390R, associated with the early-onset/severe phenotype. PMID: 19358837
49. changes in gene expression are induced by laminar shear stress as well as by cellular senescence PMID: 19409979
50. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. PMID: 19533750

显示更多

收起更多

HGNC: 758

OMIM: 215700

KEGG: hsa:445

STRING: 9606.ENSP00000253004

UniGene: Hs.160786